Raffaele Romito
Overview
Explore the profile of Raffaele Romito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boggi U, Kauffmann E, Napoli N, Barreto S, Besselink M, Fusai G, et al.
Ann Surg
. 2024 Feb;
280(1):56-65.
PMID: 38407228
Objective: The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Background: Coupled...
2.
Frosio F, Masserano R, Colli F, Portigliotti L, Maroso F, Nicolosi F, et al.
Cureus
. 2022 Dec;
14(11):e31227.
PMID: 36514587
Introduction The importance of coronavirus disease (COVID)-free surgical pathways during the coronavirus disease 2019 (COVID-19) pandemic has been demonstrated. However, the extent of protective measures to be applied against severe...
3.
Grossini E, Garhwal D, Calamita G, Romito R, Rigamonti C, Minisini R, et al.
Front Med (Lausanne)
. 2021 Jul;
8:693997.
PMID: 34277668
Changes of lipidic storage, oxidative stress and mitochondrial dysfunction may be involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Although the knowledge of intracellular pathways has vastly expanded...
4.
DeAngelis N, Catena F, Memeo R, Coccolini F, Martinez-Perez A, Romeo O, et al.
World J Emerg Surg
. 2021 Jun;
16(1):30.
PMID: 34112197
Bile duct injury (BDI) is a dangerous complication of cholecystectomy, with significant postoperative sequelae for the patient in terms of morbidity, mortality, and long-term quality of life. BDIs have an...
5.
Pirisi M, Leutner M, Romito R, Gaia S
J Clin Gastroenterol
. 2020 Aug;
54(9):789-794.
PMID: 32773489
Among clinicians, the users of medical calculators have expanded in recent years to an unprecedented number. The usefulness of some of these calculators is sometimes debatable, and experienced professionals may...
6.
Farruggio S, Cocomazzi G, Marotta P, Romito R, Surico D, Calamita G, et al.
Cell Physiol Biochem
. 2020 Apr;
54(3):401-416.
PMID: 32330379
Background/aims: Oxidative stress and mitochondria dysfunction could be involved in the onset of non-alcoholic fatty liver disease (NAFLD) and in its progression to non-alcoholic steatohepatitis (NASH). Estrogens/phytoestrogens could counteract liver...
7.
Pirovano A, Matino E, Zecca E, Costanzo M, Croce A, Leutner M, et al.
Eur J Case Rep Intern Med
. 2019 Jun;
6(5):001061.
PMID: 31157180
Learning Points: Lymphomas may present with serous effusion, which is usually chylous and with positive cytology when represented by ascites accumulation; non-chylous effusions can be due to altered lymphatic drainage,...
8.
Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, et al.
J Hepatol
. 2018 Jan;
68(4):724-732.
PMID: 29331342
Background & Aims: Yttrium-90 transarterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC), associated with portal vein tumor thrombus (PVTT). The aim of...
9.
Spreafico C, Morosi C, Maccauro M, Romito R, Lanocita R, Civelli E, et al.
Cardiovasc Intervent Radiol
. 2014 Jun;
38(2):322-8.
PMID: 24927964
Introduction: In planning Yttrium-90 ((90)Y)-radioembolizations, strategy problems arise in tumours with multiple arterial supplies. We aim to demonstrate that tumours can be treated via one main feeding artery achieving flow...
10.
Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al.
Hepatology
. 2012 Aug;
57(5):1826-37.
PMID: 22911442
Unlabelled: Yttrium-90 radioembolization (Y90RE) is a novel approach to radiation therapy for hepatocellular carcinoma (HCC), never tested in phase 2 studies. Fifty-two patients with intermediate (n.17) to advanced (n.35) HCC...